Clinical Trial

Novel Soluble Epoxide Hydrolase Inhibitor for Neuropathic Pain in Patients With Spinal Cord Injury

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The goal of this clinical trial is to evaluate safety and tolerability of multiple oral doses of EC5026 in male and female patients with neuropathic pain due to traumatic or non-traumatic (degenerative) spinal cord injury. The main question it aims to answer is whether EC5026 is safe and well tolerated in SCI patients with neuropathic pain. In addition, this trial will also study the effects of EC5026 on pain. Researchers will compare EC5026 to placebo. Participants will be asked to: * Take EC5026 or placebo in a masked fashion, once daily, for 14 consecutive days. * Undergo physical exams, vital signs assessments, ECGs, and blood draws * Complete assessments of pain, sleep, functional status, and perception of change
Protocol Amendment History 2 changes
notable Primary completion pushed: 2027-02 -> 2027-12 2026-07-11
minor Completion pushed: 2027-06 -> 2027-12 2026-07-11
Trial Details
NCT Number NCT06438471
Lead Sponsor EicOsis Human Health Inc.
Collaborators: Congressionally Directed Medical Research Programs
Conditions Spinal Cord Injuries, Neuropathic Pain, Degenerative Disc Disease, Spinal Stenosis, Spondylosis
Enrollment 36 participants
Start Date 2026-05-01
Primary Completion 2027-12 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2026-07-10